24.69
-0.13(-0.52%)
Currency In USD
| Previous Close | 24.82 |
| Open | 24.51 |
| Day High | 24.79 |
| Day Low | 24.38 |
| 52-Week High | 26.58 |
| 52-Week Low | 19.05 |
| Volume | 590,924 |
| Average Volume | 1.24M |
| Market Cap | 3.03B |
| PE | 14.7 |
| EPS | 1.68 |
| Moving Average 50 Days | 24.07 |
| Moving Average 200 Days | 22.22 |
| Change | -0.13 |
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 06, 2026 1:03 PM GMT
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients li
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
GlobeNewswire Inc.
Feb 24, 2026 1:03 PM GMT
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
GlobeNewswire Inc.
Feb 11, 2026 1:03 PM GMT
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ETCORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage bioph